|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Ahn HS, Kim HJ and Welch HG: Korea's
thyroid-cancer 'epidemic' - screening and overdiagnosis. N Engl J
Med. 371:1765–1767. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen AY, Jemal A and Ward EM: Increasing
incidence of differentiated thyroid cancer in the United States,
1988-2005. Cancer. 115:3801–3807. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schlumberger MJ: Papillary and follicular
thyroid carcinoma. N Engl J Med. 338:297–306. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sherman SI: Thyroid carcinoma. Lancet.
361:501–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Muresan MM, Olivier P, Leclère J, Sirveaux
F, Brunaud L, Klein M, Zarnegar R and Weryha G: Bone metastases
from differentiated thyroid carcinoma. Endocr Relat Cancer.
15:37–49. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tubiana M, Schlumberger M, Rougier P,
Laplanche A, Benhamou E, Gardet P, Caillou B, Travagli JP and
Parmentier C: Long-term results and prognostic factors in patients
with differentiated thyroid carcinoma. Cancer. 55:794–804. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Smallridge RC and Copland JA: Anaplastic
thyroid carcinoma: Pathogenesis and emerging therapies. Clin Oncol
(R Coll Radiol). 22:486–497. 2010. View Article : Google Scholar
|
|
9
|
Smallridge RC, Ain KB, Asa SL, Bible KC,
Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal
MS, et al American Thyroid Association Anaplastic Thyroid Cancer
Guidelines Taskforce: American Thyroid Association guidelines for
management of patients with anaplastic thyroid cancer. Thyroid.
22:1104–1139. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nosé V: Familial thyroid cancer: A review.
Mod Pathol. 24(Suppl 2): S19–S33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Williams SD, Birch R and Einhorn LH: Phase
II evaluation of doxorubicin plus cisplatin in advanced thyroid
cancer: A Southeastern Cancer Study Group Trial. Cancer Treat Rep.
70:405–407. 1986.PubMed/NCBI
|
|
12
|
Bikas A, Vachhani S, Jensen K, Vasko V and
Burman KD: Targeted therapies in thyroid cancer: An extensive
review of the literature. Expert Rev Clin Pharmacol. 9:1299–1313.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kushchayeva Y, Jensen K, Burman KD and
Vasko V: Repositioning therapy for thyroid cancer: New insights on
established medications. Endocr Relat Cancer. 21:R183–R194. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jensen K, Bikas A, Patel A, Kushchayeva Y,
Costello J, McDaniel D, Burman K and Vasko V: Nelfinavir inhibits
proliferation and induces DNA damage in thyroid cancer cells.
Endocr Relat Cancer. 24:147–156. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kushchayeva Y, Jensen K, Recupero A,
Costello J, Patel A, Klubo-Gwiezdzinska J, Boyle L, Burman K and
Vasko V: The HIV protease inhibitor nelfinavir down-regulates RET
signaling and induces apoptosis in medullary thyroid cancer cells.
J Clin Endocrinol Metab. 99:E734–E745. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Klubo-Gwiezdzinska J, Jensen K, Costello
J, Patel A, Hoperia V, Bauer A, Burman KD, Wartofsky L and Vasko V:
Metformin inhibits growth and decreases resistance to anoikis in
medullary thyroid cancer cells. Endocr Relat Cancer. 19:447–456.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thakur S, Daley B, Gaskins K, Vasko VV,
Boufraqech M, Patel D, Sourbier C, Reece J, Cheng SY, Kebebew E, et
al: Metformin targets mitochondrial glycerophosphate dehydrogenase
to control rate of oxidative phosphorylation and growth of thyroid
cancer in vitro and in vivo. Clin Cancer Res. 24:4030–4043. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Baudry C, Coste J, Bou Khalil R, Silvera
S, Guignat L, Guibourdenche J, Abbas H, Legmann P, Bertagna X and
Bertherat J: Efficiency and tolerance of mitotane in Cushing's
disease in 76 patients from a single center. Eur J Endocrinol.
167:473–481. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Berruti A, Baudin E, Gelderblom H, Haak
HR, Porpiglia F and Fassnacht M; Adrenal cancer: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 23(Suppl 7): vii131–vii138. 2012. View Article : Google Scholar
|
|
20
|
Henley DJ, van Heerden JA, Grant CS,
Carney JA and Carpenter PC: Adrenal cortical carcinoma - a
continuing challenge. Surgery. 94:926–931. 1983.PubMed/NCBI
|
|
21
|
Hescot S, Slama A, Lombès A, Paci A, Remy
H, Leboulleux S, Chadarevian R, Trabado S, Amazit L, Young J, et
al: Mitotane alters mitochondrial respiratory chain activity by
inducing cytochrome c oxidase defect in human adrenocortical cells.
Endocr Relat Cancer. 20:371–381. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Poli G, Guasti D, Rapizzi E, Fucci R, Canu
L, Bandini A, Cini N, Bani D, Mannelli M and Luconi M:
Morphofunctional effects of mitotane on mitochondria in human
adrenocortical cancer cells. Endocr Relat Cancer. 20:537–550. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
24
|
Schteingart DE, Doherty GM, Gauger PG,
Giordano TJ, Hammer GD, Korobkin M and Worden FP: Management of
patients with adrenal cancer: Recommendations of an international
consensus conference. Endocr Relat Cancer. 12:667–680. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Haak HR, Hermans J, van de Velde CJ,
Lentjes EG, Goslings BM, Fleuren GJ and Krans HM: Optimal treatment
of adrenocortical carcinoma with mitotane: Results in a consecutive
series of 96 patients. Br J Cancer. 69:947–951. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hermsen IG, Fassnacht M, Terzolo M,
Houterman S, den Hartigh J, Leboulleux S, Daffara F, Berruti A,
Chadarevian R, Schlumberger M, et al: Plasma concentrations of o,
p'DDD, o, p'DDA, and o, p'DDE as predictors of tumor response to
mitotane in adrenocortical carcinoma: Results of a retrospective
ENS@T multicenter study. J Clin Endocrinol Metab. 96:1844–1851.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
van Slooten H, Moolenaar AJ, van Seters AP
and Smeenk D: The treatment of adrenocortical carcinoma with o,
p'-DDD: Prognostic implications of serum level monitoring. Eur J
Cancer Clin Oncol. 20:47–53. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Baudin E; Endocrine Tumor Board of Gustave
Roussy: Adrenocortical carcinoma. Endocrinol Metab Clin North Am.
44:411–434. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lehmann TP, Wrzesiński T and Jagodziński
PP: The effect of mitotane on viability, steroidogenesis and gene
expression in NCI-H295R adrenocortical cells. Mol Med Rep.
7:893–900. 2013. View Article : Google Scholar
|
|
30
|
Waszut U, Szyszka P and Dworakowska D:
Understanding mitotane mode of action. J Physiol Pharmacol.
68:13–26. 2017.PubMed/NCBI
|
|
31
|
Pinton P, Giorgi C, Siviero R, Zecchini E
and Rizzuto R: Calcium and apoptosis: ER-mitochondria Ca2+ transfer
in the control of apoptosis. Oncogene. 27:6407–6418. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sbiera S, Leich E, Liebisch G, Sbiera I,
Schirbel A, Wiemer L, Matysik S, Eckhardt C, Gardill F, Gehl A, et
al: Mitotane inhibits sterol-O-acyl transferase 1 triggering
lipid-mediated endoplasmic reticulum stress and apoptosis in
adrenocortical carcinoma cells. Endocrinology. 156:3895–3908. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fang VS: Cytotoxic activity of
1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (mitotane)
and its analogs on feminizing adrenal neoplastic cells in culture.
Cancer Res. 39:139–145. 1979.PubMed/NCBI
|
|
34
|
Hescot S, Amazit L, Lhomme M, Travers S,
DuBow A, Battini S, Boulate G, Namer IJ, Lombes A, Kontush A, et
al: Identifying mitotane-induced mitochondria-associated membranes
dysfunctions: Metabolomic and lipidomic approaches. Oncotarget.
8:109924–109940. 2017. View Article : Google Scholar
|
|
35
|
Whelan SP and Zuckerbraun BS:
Mitochondrial signaling: Forwards, backwards, and in between. Oxid
Med Cell Longev. 2013:3516132013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen H and Chan DC: Physiological
functions of mitochondrial fusion. Ann N Y Acad Sci. 1201:21–25.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hutter AM Jr and Kayhoe DE: Adrenal
cortical carcinoma. Clinical features of 138 patients. Am J Med.
41:572–580. 1966. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Veytsman I, Nieman L and Fojo T:
Management of endocrine manifestations and the use of mitotane as a
chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol.
27:4619–4629. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Creemers SG, Hofland LJ, Korpershoek E,
Franssen GJ, van Kemenade FJ, de Herder WW and Feelders RA: Future
directions in the diagnosis and medical treatment of adrenocortical
carcinoma. Endocr Relat Cancer. 23:R43–R69. 2016. View Article : Google Scholar
|
|
40
|
Morishita K, Okumura H, Ito N and
Takahashi N: Primary culture system of adrenocortical cells from
dogs to evaluate direct effects of chemicals on steroidogenesis.
Toxicology. 165:171–178. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zatelli MC, Gentilin E, Daffara F,
Tagliati F, Reimondo G, Carandina G, Ambrosio MR, Terzolo M and
Degli Uberti EC: Therapeutic concentrations of mitotane (o, p'-DDD)
inhibit thyrotroph cell viability and TSH expression and secretion
in a mouse cell line model. Endocrinology. 151:2453–2461. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Russo M, Scollo C, Pellegriti G, Cotta OR,
Squatrito S, Frasca F, Cannavò S and Gullo D: Mitotane treatment in
patients with adrenocortical cancer causes central hypothyroidism.
Clin Endocrinol (Oxf). 84:614–619. 2016. View Article : Google Scholar
|
|
43
|
Chortis V, Taylor AE, Schneider P,
Tomlinson JW, Hughes BA, O'Neil DM, Libé R, Allolio B, Bertagna X,
Bertherat J, et al: Mitotane therapy in adrenocortical cancer
induces CYP3A4 and inhibits 5α-reductase, explaining the need for
personalized glucocorticoid and androgen replacement. J Clin
Endocrinol Metab. 98:161–171. 2013. View Article : Google Scholar
|
|
44
|
van Staveren WC, Solís DW, Delys L, Duprez
L, Andry G, Franc B, Thomas G, Libert F, Dumont JE, Detours V, et
al: Human thyroid tumor cell lines derived from different tumor
types present a common dedifferentiated phenotype. Cancer Res.
67:8113–8120. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Saiselet M, Floor S, Tarabichi M, Dom G,
Hébrant A, van Staveren WC and Maenhaut C: Thyroid cancer cell
lines: An overview. Front Endocrinol (Lausanne). 3:1332012.
View Article : Google Scholar
|
|
46
|
Salehian B, Liem SY, Mojazi Amiri H and
Maghami E: Clinical Trials in Management of Anaplastic Thyroid
Carcinoma; Progressions and Set Backs: A Systematic Review. Int J
Endocrinol Metab. 17:e677592019.PubMed/NCBI
|
|
47
|
Sosa JA, Elisei R, Jarzab B, Balkissoon J,
Lu SP, Bal C, Marur S, Gramza A, Yosef RB, Gitlitz B, et al:
Randomized safety and efficacy study of fosbretabulin with
paclitaxel/carboplatin against anaplastic thyroid carcinoma.
Thyroid. 24:232–240. 2014. View Article : Google Scholar
|
